Pseudomonas Infections — Pharmacokinetic Evaluation of an 8 -Week Treatment With Inhaled Tobramycin
Citation(s)
A Multicenter, Open Label, 2 Period Cross-over Study to Evaluate the PK of a 8 Week Continuous Treatment With 1x300mg/d and 2x300mg/d Tobramycin Inhaled With a 'Soft Mist' Nebulizer in Cystic Fibrosis (CF) Subjects